Drug intelligence / Profile preview

FB1001

Development stage: Phase 1
Lead developer: Fubei Biotechnology
Modality: Antibody-Based Therapeutics
Administration: Intravitreal, Ophthalmic

Overview

FB1001 is an investigational antibody drug developed by Fubei Biotechnology (Suzhou) Co., Ltd. (also referenced as 4B Technologies in some sources) for the treatment of optic nerve diseases, including acute optic neuropathy and glaucoma. Its mechanism of action is as a TrkB stimulant, meaning it targets and stimulates the tropomyosin receptor kinase B (TrkB), which plays a key role in neuronal survival and regeneration. The drug is administered via injection, specifically intravitreal injection for ophthalmic indications. As of April 2025, FB1001 is in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with acute optic neuropathy[1][2][3].

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on FB1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FB1001.

Explore the full profile